Irritable bowel syndrome: focus on otilonium bromide
作者： Guy Boeckxstaens , Pere Clavé , Enrico S Corazziari , Jan Tack
DOI: 10.1586/17474124.2014.869477
关键词: Otilonium bromide 、 Diarrhea 、 Irritable bowel syndrome 、 Abdominal pain 、 Gastroenterology 、 Placebo 、 Constipation 、 Medicine 、 Bloating 、 Internal medicine 、 Population
摘要: Irritable bowel syndrome is a prevalent and chronic disorder, characterized by recurrent abdominal pain/discomfort, bloating altered habits. This condition affects an estimated 10-15% of the population worldwide impacts heavily on patient's daily life ability to work, as well healthcare resource utilization. Drug therapy aimed at correcting primary symptoms diarrhea/constipation/bloating may have little effect pain, which results from visceral hypersensitivity. Smooth muscle relaxants or antispasmodics decrease tone contractility intestinal smooth muscle, effectively managing pain. Otilonium bromide has been widely used found be safe tolerated, superior placebo for reduction prevention symptom relapse in patients with irritable syndrome.
informahealthcare.com
core.ac.uk 参考文章(30)
P. Clavé, M. Acalovschi, J. K. Triantafillidis, Y. P. Uspensky, C. Kalayci, V. Shee, J. Tack, , Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome Alimentary Pharmacology & Therapeutics. ,vol. 34, pp. 432- 442 ,(2011) , 10.1111/J.1365-2036.2011.04730.X
G. Cipriani, P. Santicioli, S. Evangelista, C. A. Maggi, S. Riccadonna, M. N. Ringressi, P. Bechi, M. S. Faussone-Pellegrini, M. G. Vannucchi, Effect of otilonium bromide and ibodutant on the internalization of the NK2 receptor in human colon Neurogastroenterology and Motility. ,vol. 23, pp. 96- ,(2011) , 10.1111/J.1365-2982.2010.01594.X
D. Gallego, M. Aulí, J. Aleu, E. Martínez, L. Rofes, J. Martí-ragué, M. Jiménez, P. Clavé, Effect of otilonium bromide on contractile patterns in the human sigmoid colon. Neurogastroenterology and Motility. ,vol. 22, ,(2010) , 10.1111/J.1365-2982.2010.01495.X
Casini A, Defrance P, A comparison of the action of otilonium bromide and pinaverium bromide: study conducted under clinical control. The Italian journal of gastroenterology. ,vol. 23, pp. 64- ,(1991)
S Evangelista, Otilonium Bromide: A Selective Spasmolytic for the Gastrointestinal Tract Journal of International Medical Research. ,vol. 27, pp. 207- 222 ,(1999) , 10.1177/030006059902700501
A. P. S. Hungin, P. J. Whorwell, J. Tack, F. Mearin, The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Alimentary Pharmacology & Therapeutics. ,vol. 17, pp. 643- 650 ,(2003) , 10.1046/J.1365-2036.2003.01456.X
Antonella Spinelli, Irritable bowel syndrome. Clinical Drug Investigation. ,vol. 27, pp. 15- 33 ,(2007) , 10.2165/00044011-200727010-00002
Douglas A. Drossman, Carolyn B. Morris, Yuming Hu, Brenda B. Toner, Nicholas Diamant, Jane Leserman, Michael Shetzline, Christine Dalton, Shrikant I. Bangdiwala, A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology. ,vol. 128, pp. 580- 589 ,(2005) , 10.1053/J.GASTRO.2004.12.006
C MAGGI, TACHYKININS AS PERIPHERAL MODULATORS OF PRIMARY AFFERENT NERVES AND VISCERAL SENSITIVITY Pharmacological Research. ,vol. 36, pp. 153- 169 ,(1997) , 10.1006/PHRS.1997.0219
Laura Quartara, Maria Altamura, Stefano Evangelista, Carlo A Maggi, Tachykinin receptor antagonists in clinical trials Expert Opinion on Investigational Drugs. ,vol. 18, pp. 1843- 1864 ,(2009) , 10.1517/13543780903379530